CVS Health Corp (NYSE:CVS) is a leading entity in the healthcare sector, offering a comprehensive range of services including pharmacy benefits management, retail pharmacy, and health insurance. The company stands in competition with other healthcare giants like Walgreens and UnitedHealth Group. On October 30, 2025, RBC Capital upgraded CVS to an "Outperform" rating, with the stock priced at $76.68. RBC Capital also raised the price target from $81 to $93.
CVS recently showcased impressive third-quarter earnings, exceeding expectations and uplifting its annual guidance. The company achieved sales of $102.87 billion, surpassing the consensus estimate of $98.84 billion. This represents a 7.8% increase in total revenues year-over-year, propelled by growth across all segments. Following this positive performance, the stock reached a 52-week high.
Despite a GAAP diluted loss per share of $3.13 due to a $5.7 billion goodwill impairment charge, CVS reported adjusted earnings per share of $1.60, outperforming the analyst estimate of $1.37. Adjusted operating income saw a significant rise of 35.8% to $3.46 billion, mainly attributed to growth in the Health Care Benefits segment, although there were declines in the Health Services and Pharmacy and Consumer Wellness segments.
Furthermore, CVS is gearing up to collaborate with EMD Serono on the TrumpRx Fertility Program, set to launch in 2026, as reported by Benzinga. The current stock price of CVS is $76.81, reflecting a decrease of 4.70% or $3.79. Today, the stock has fluctuated between a low of $75.92 and a high of $79. Over the past year, CVS has achieved a high of $85.15 and a low of $43.56. The company's market capitalization is approximately $97.42 billion, with a trading volume of 6,168,140 shares on the NYSE.
